Bioregenx Files Q1 2024 10-Q Amendment
Ticker: BRGX · Form: 10-Q/A · Filed: Oct 9, 2024 · CIK: 1593184
| Field | Detail |
|---|---|
| Company | Bioregenx, INC. (BRGX) |
| Form Type | 10-Q/A |
| Filed Date | Oct 9, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $522,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, amendment, financials
TL;DR
Bioregenx amended its Q1 2024 10-Q. Updated financials are in.
AI Summary
Bioregenx, Inc. filed an amended 10-Q for the period ending March 31, 2024. The filing includes financial data for the first quarter of 2024 and comparative periods. Key financial items such as common stock, preferred stock, additional paid-in capital, retained earnings, and accumulated other comprehensive income are detailed for various dates, including December 31, 2023, and March 31, 2024.
Why It Matters
This amended filing provides updated financial information for Bioregenx, Inc. for the first quarter of 2024, crucial for investors assessing the company's performance and financial health.
Risk Assessment
Risk Level: low — This filing is an amendment to a quarterly report and primarily contains updated financial data, not new material events or significant changes in business operations.
Key Numbers
- 2024-03-31 — Period End Date (First quarter of 2024)
- 2023-12-31 — Prior Year End Date (Comparative financial data)
Key Players & Entities
- BIOREGENX, INC. (company) — Filer
- FINDIT, INC. (company) — Former Company Name
- ARTEMIS ENERGY HOLDINGS, INC. (company) — Former Company Name
FAQ
What is the primary purpose of this 10-Q/A filing?
This filing is an amendment (10-Q/A) to the quarterly report for Bioregenx, Inc., providing updated financial information for the period ending March 31, 2024.
What is the reporting period covered by this amended 10-Q?
The amended 10-Q covers the first quarter of 2024, with the period of report ending on March 31, 2024.
What are some of the key financial statement components detailed in the filing?
The filing details components such as Series A Preferred Stock, Common Stock, Additional Paid-In Capital, Retained Earnings, and Accumulated Other Comprehensive Income.
What were Bioregenx, Inc.'s former company names?
Bioregenx, Inc. was formerly known as FINDIT, INC. and ARTEMIS ENERGY HOLDINGS, INC.
On what date was this amended 10-Q filed?
This amended 10-Q was filed on October 9, 2024.
Filing Stats: 4,478 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-10-09 15:38:41
Key Financial Figures
- $0.001 — Section 12(g) of the Act: Common Stock, $0.001 par value Indicate by check mark whet
- $522,500 — hat date. In addition, notes payable of $522,500 were in default. At March 31, 2024, the
Filing Documents
- bioregenx_i10qa2-033124.htm (10-Q/A) — 1016KB
- bioregenx_ex0201.htm (EX-2.1) — 351KB
- bioregenx_ex0202.htm (EX-2.2) — 31KB
- bioregenx_ex1001.htm (EX-10.1) — 198KB
- bioregenx_ex1002.htm (EX-10.2) — 55KB
- bioregenx_ex3100.htm (EX-31) — 7KB
- bioregenx_ex3200.htm (EX-32) — 3KB
- image_002.jpg (GRAPHIC) — 501KB
- image_003.jpg (GRAPHIC) — 356KB
- image_004.jpg (GRAPHIC) — 248KB
- image_005.jpg (GRAPHIC) — 222KB
- image_006.jpg (GRAPHIC) — 239KB
- image_015.jpg (GRAPHIC) — 7KB
- image_007.jpg (GRAPHIC) — 10KB
- 0001683168-24-007021.txt ( ) — 9949KB
- brgx-20240331.xsd (EX-101.SCH) — 73KB
- brgx-20240331_cal.xml (EX-101.CAL) — 57KB
- brgx-20240331_def.xml (EX-101.DEF) — 250KB
- brgx-20240331_lab.xml (EX-101.LAB) — 454KB
- brgx-20240331_pre.xml (EX-101.PRE) — 403KB
- bioregenx_i10qa2-033124_htm.xml (XML) — 1158KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements Condensed Consolidated Balance Sheets as of March 31, 2024 (As Restated) (unaudited) and December 31, 2023 (audited) 4 Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2024 and 2023 (unaudited) 5 Condensed and Consolidated Statement of Stockholders' Equity (Deficit) (As Restated) for the three months ended March 31, 2024 and 2023 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for three months ended March 31, 2024 (As Restated) and 2023 (unaudited) 7 Notes to the Financial Statements for the three months ended March 31, 2024 (As Restated) and 2023 (unaudited) 8 3 BIOREGENX, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS As of March 31, 2024 (As Restated) As of December 31, 2023 ASSETS Current Assets: Cash and cash equivalents $ 114,158 $ 125,402 Accounts receivable 11,175 104,581 Inventories, net 213,343 217,529 Prepaid expenses and other current assets 146,788 205,152 Total Current Assets 485,464 652,664 Property and equipment, net 233,135 13,723 Intangible assets, provisional, net 10,795,865 49,363 Goodwill, provisional 7,105,522 – Other Assets – 150,000 Total Assets $ 18,619,986 $ 865,750 LIABILITIES & STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable $ 370,857 $ 241,695 Accounts payable – related parties 181,601 213,516 Accrued expenses 362,687 346,677 Accrued interest - related parties 321,897 292,190 Promissory notes payable and loans (including $ 522,500 and $ 322,500 in default) 849,491 375,681 Promissory notes payable and loans – related parties 963,215 963,215 Deferred revenue 334,939 354,203 Total current liabilities 3,384,687 2,787,177 Notes payable 150,000 150,000 Total Liabilities 3,534,687 2,937,177 Stockholders' Equity (Deficit): Common stock, $ 0.001 par value, 1,500,000,000 shares authorized, 956,530,100 issued and outst